What Happened?
, -based Chimerix Promoted Andrew Rogers as Assistant General Counsel
About the Company
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.
About the Person
Andrew Rogers is Assistant General Counsel at Chimerix. Previously, Andrew held various senior legal leadership roles in the industry.
Info Source
News
Short Profile